Loading
PB
Passage BIO, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 Sept 2025.
Passage BIO, Inc.: what insiders have been doing
Every trade that managers of Passage BIO, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 2 insiders published 2 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
No insider has bought Passage BIO, Inc. shares on the open market in the past twelve months.
With 2 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 13 purchases and 11 sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
38
Thresholds
n/a
Buy Volume
€3M
13 ops. · all time
Sell Volume
€498,455
11 ops. · all time
Who traded when
BuySaleOrbimed Advisors LLC8 sales
Lynx1 Capital Management LP4 buys
Since the insiders bought
- -33.1%Entry US$7.27 · Close at T+365 US$4.86
- -54.7%Entry US$44.60 · Close at T+365 US$20.20
- -66.2%Entry US$61.60 · Close at T+365 US$20.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.40
Analyst consensus
2 analystsUS$8.00Target US$15.50(+252%)US$23.00
Income statement
EBITDA-US$42.4M
Net income-US$45.5M0.0% margin
Valuation
PER (forward)-0.4x
P/Book1.2x
Beta1.43
Balance sheet & cash
Market capUS$14.1M
Total debtUS$24M
Free Cash Flow-US$31.5M
Debt / Equity49%
Profitability & ownership
ROE-128.9%
ROA-39.0%
% insiders7.7%
% institutions58.9%
Last declaration on 12 January 2026
Declarations38 total
5,000 sharesCommon StockSEC:0001987062-26-000001:0
10,000 sharesCommon StockSEC:0001949693-26-000001:0
325 shares@ US$6.95580.4% of flowCommon stock, $0.0001 par value per share (Common Stock)SEC:0000902664-25-004079:0
Canonical exit: 10 Dec 2025 (T+90)
13,123 shares@ US$5.436114.0% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-25-003152:0
Canonical exit: 20 Oct 2025 (T+90)
231,600 shares@ US$0.352.0% of flowCommon StockSEC:0000947871-25-000629:0
78,049 shares@ US$0.340.7% of flowCommon StockSEC:0000947871-25-000423:0
10,326 shares@ US$0.380.1% of flowCommon StockSEC:0000947871-25-000415:0
8,000 sharesCommon StockSEC:0001415889-25-003728:0
126,209 shares@ US$0.662.3% of flowCommon StockSEC:0000947871-25-000034:0
19,481 shares@ US$0.770.4% of flowCommon StockSEC:0000947871-25-000021:0
373,645 shares@ US$0.645153.3% of flowCommon stock, $0.0001 par value per shareSEC:0000902664-24-007075:0
Canonical exit: 27 Mar 2025 (T+90)
230,321 shares@ US$0.603.9% of flowCommon StockSEC:0000947871-24-001037:0
54,181 shares@ US$0.841.2% of flowCommon StockSEC:0000947871-24-000998:0
76,200 shares@ US$0.791.7% of flowCommon StockSEC:0000947871-24-000995:0
259,998 shares@ US$0.564132.3% of flowCommon stock, $0.0001 par value per share ("Common Stock")SEC:0000902664-24-006799:0
Canonical exit: 23 Feb 2025 (T+90)
39,300 shares@ US$0.710.7% of flowCommon StockSEC:0000947871-24-000769:0
63,100 shares@ US$0.741.2% of flowCommon StockSEC:0000947871-24-000763:0
5,000 sharesCommon StockSEC:0001415889-24-003637:0
4,000 sharesCommon StockSEC:0001415889-24-003640:0
30,000 sharesCommon StockSEC:0001209191-24-000367:0
50,000 sharesCommon StockSEC:0001209191-24-000365:0
50,000 sharesCommon StockSEC:0001209191-24-000369:0
31,250 shares0Common StockSEC:0001209191-23-043998:0
617,382 shares@ US$0.8413.7% of flowCommon StockSEC:0000947871-23-000712:0
Canonical exit: 25 Sept 2023 (T+90)
12,500 shares0Common StockSEC:0001209191-23-038345:0
25 of 38 declarations
About Passage BIO, Inc.
Passage Bio, Inc. (NASDAQ: PASG) is a United States-based clinical-stage genetic medicines company headquartered in Philadelphia, Pennsylvania. Founded in July 2017, the company focuses on developing one-time, disease-modifying therapies aimed at the underlying biology of neurodegenerative disorders. For investors, Passage Bio remains a high-risk, development-stage biotechnology name with no meaningful commercial revenue to date and a business model still centered on clinical execution, regulatory milestones, and external funding. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf))
The company’s origins are closely tied to its research and collaboration framework with the University of Pennsylvania’s Gene Therapy Program, which helped establish Passage Bio’s scientific base and early pipeline. This collaboration was originally built around rare, monogenic central nervous system diseases and later supported the company’s broader push into neurodegenerative indications. That historical tie remains important because it underpins Passage Bio’s access to scientific know-how and gene therapy expertise. ([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-announces-expansion-of-gene-therapy-collaboration-with-university-of))
Read moreShow less
Passage Bio’s lead clinical asset is PBFT02, a candidate being developed for frontotemporal dementia, including FTD associated with progranulin deficiency. The company describes the mechanism as raising progranulin levels to restore lysosomal function and potentially slow disease progression. Strategically, this places Passage Bio in a highly specialized segment of the CNS biotech market where scientific differentiation matters, but where clinical and regulatory risk is also substantial. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf))
From a competitive standpoint, Passage Bio is not yet a commercial-stage peer and does not compete on scale, sales infrastructure, or diversified product revenue. Instead, its value proposition rests on pipeline optionality, platform credibility, and the potential to advance a small number of genetically targeted programs into later-stage development. SEC filings show recurring losses, a large accumulated deficit, and continuing dependence on equity financings, collaborations, and licensing arrangements to fund operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001787297/000155837025004879/pasg-20241231xars.pdf))
Recent developments have been notable. The company reported updated interim data from the upliFT-D trial and stated that a strategic review is underway; it also disclosed that Wedbush PacGrow has been engaged as financial advisor for that process. Passage Bio has continued to present at investor conferences in 2025 and 2026, reflecting ongoing capital-markets engagement while it works through clinical, regulatory, and corporate priorities. For U.S. investors following insider activity, this NASDAQ-listed name remains a speculative biotech story where execution, financing flexibility, and readouts on PBFT02 are the key drivers. ([nasdaq.com](https://www.nasdaq.com/press-release/passage-bio-reports-updated-interim-data-uplift-d-trial-and-provides-regulatory-and))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
